Prostate Cancer - Discussions
STAMPEDE, ARANOTE, ARASENS
ASCO GU 2025
Milestones of ADT and ARPI treatment in the metastastic…
TALAPRO-2
ASCO GU 2025
Combining ARPi with PARPi - discussing final OS of…
ENZA-p
ASCO GU 2025
What's the role of Enzalutamide in radioligand therapy?
Prostate Cancer - 100 seconds
WOLVERINE
ASCO GU 2025
MDT in OMPC
MEDI 4736
ASCO GU 2025
Durvalumab in UTUC
ASCO GU 2025
Radical Prostatectomy VS RT in HRPC
TALAPRO-2
ASCO GU 2025
OS in the TALAPRO-2 trial
ASCO GU 2025
Radiation vs surgery in high risk prostate cancer
STOPCAP
ASCO GU 2025
ARPI for which patients?
ASCO GU 2025
Hypo-gonadism bad for survival?
CAPFISH-3
ASCO GU 2025
Fish-oil supplement for pts on active surveillance
ARANOTE
ASCO GU 2025
Darolutamide + ADT reduces risk of progression or death…
ENZA-p
ASCO GU 2025
ENZA-p showed OS benefit and improvement in QoL…
TALAPRO-2
ASCO GU 2025
Final OS analyses
ASCO GU 2025
Phase 2 Mevrometostat
ASCO GU 2025
Testosterone Recovery
GROUQ-PCS 9
ASCO GU 2025
Local radiotherapy of oligoprogressive mCRPC
ARASENS
ASCO GU 2025
Darolutamide + ADT and Doetaxel improves survivas in…
ASCO GU 2025
Mevrometostat - a new EZH2 inhibitor in mCRPC
ASCO GU 2025
Mevrometostat + Enza: New option for mCRPC
ENZA-P
ASCO GU 2025
Improved Survival with Enzalutamide + Lutetium
TALAPRO-2
ASCO GU 2025
Final OS data for TALA + Enza
STOPCAP
ASCO GU 2025
Who benefits most from ARPIs?
ASCO GU 2025
Testosterone Recovery after ADT and OS
Prostate Cancer - 100 seconds multi language
WOLVERINE
ASCO GU 2025
Oligometastatik PCa da MDT
MEDI 4736
ASCO GU 2025
UTUC de Neoadj. Durvalumab+Kemo
STOPCAP
ASCO GU 2025
Hangi hastalarda ADT+ARPI
ASCO GU 2025
Yuksek risk PCa da RP vs RT
ASCO GU 2025
Testosteron Geri Gelisi ve Sagkalim
ENZA-P
ASCO GU 2025
Enza+Lu ile artmis sagkalim
Renal Cell Carcinoma - Discussions
CheckMate 214
ASCO GU 2025
KIM-1 - The most interesting biomarker for RCC?
CheckMate 9ER
ASCO GU 2025
New data but no new conclusion
COSMIC-313
ASCO GU 2025
Triplet combination in RCC - there's no free lunch with…
ARC-20
ASCO GU 2025
Exciting new substances - but don't over-estimate phase…
Renal Cell Carcinoma - 100 seconds
COSMIC-313
ASCO GU 2025
Advanced Renal Cell Cancer: Adding more drugs does not…
PREPARE
ASCO GU 2025
Proactive coaching of patients with TKI +/- IO therapy
GUARDIANS
ASCO GU 2025
New data nccRCC
CheckMate 214
ASCO GU 2025
KIM-1 in mRCC
CheckMate 9ER
ASCO GU 2025
Firstline Update Kidney Cancer
ARC-20
ASCO GU 2025
Casdatifan in refracting RCC
CheckMate 214
ASCO GU 2025
Prognostic and predictive biomarkers in mRCC: Looking…
CheckMate 214
ASCO GU 2025
KIM-1 in CheckMate 214
AVION
ASCO GU 2025
AVION trial at mRCC
KEYMAKER-U03
ASCO GU 2025
New agents / new mode of actions
Renal Cell Carcinoma - 100 seconds multi language
CheckMate 214
ASCO GU 2025
Biomarcadores prognósticos y predictivos en el CCRm: en…
COSMIC-313
ASCO GU 2025
Cáncer de células renales avanzado: añadir más fármacos…
Urothelial Cancer - Discussions
EV-302, MK-2870-001, TROPIONPanTumor01
ASCO GU 2025
Reassuring data on established ADCs and new insights in…
MEDI 4736
ASCO GU 2025
Neoadjuvant chemo-immunotherapy in UTUC: new evidence…
CheckMate 274
ASCO GU 2025
New data, but no new insights for adjuvant treatment of…
NIAGARA
ASCO GU 2025
Exploratory analyses of pCR in NIAGARA: who benefits…
RC48-C017
ASCO GU 2025
ADC + ICI - The future for MIBC?
Urothelial Cancer - 100 seconds
EV-302
ASCO GU 2025
EV-Pembro continues to be the standard for mTCC
MK-2870-001
ASCO GU 2025
Sacituzumab Tirumotecan shows promising antitumor…
MK-2870-001
ASCO GU 2025
New drugs in mUC: The active field of ADCs
NIAGARA, CheckMate 274
ASCO GU 2025
Updates neo/adjuvant therapy in MIBC
NIAGARA, CheckMate 274, EV-302
ASCO GU 2025
ASCO GU 25 - Summary: Urothelial Cancer
CheckMate 274
ASCO GU 2025
Adjuvant Nivo - independent from previous therapy
ASCO GU 2025
Phase 2 Mevrometastat
General Session Urothelial cancer
ASCO GU 2025
The role of ctDNA in bladder cancer
NIAGARA
ASCO GU 2025
A possible new standard for mUC
FORAGER-1
ACO GU 2025
New FGFR3 inhibitor
MEDI 4736
ASCO GU 2025
Durvalumab + Platinum-based chemotherapy shows…
RC48-C017
ASCO GU 2025
Promising combination for perioperative setting
NIAGARA
ASCO GU 2025
Bladder-sparing approaches - are we there yet?
CheckMate 274
ASCO GU 2025
Nivo adjuvant in MIBC - a new standard
iNDUCT-2
ASCO GU 2025
Preliminary results of neoadjuvant chemoimmunotherapy…
ASCO GU 2025
Neoadjuvant treatment for UTUC
RC48-071
ASCO GU 2025
HER2 - new marker for bladder preservation
Urothelial Cancer - 100 seconds multi language
NIAGARA, CheckMate 274, EV-302
ASCO GU 2025
ASCO GU 25 - Περίληψη: Ουροθηλιακός καρκίνος
RC48-C017
ASCO GU 2025
Promising combination for perioperative setting
MK-2870-001
ASCO GU 2025
Nuevos fármacos en mUC: El campo activo de las ADCs
Seminoma - 100 seconds
COTRIMS
ASCO GU 2025
Testicular cancer: Reinventing the wheel
COTRIMS
ASCO GU 2025
RPLND in metastatic Seminoma
Seminoma - 100 seconds multi language
COTRIMS
ASCO GU 2025
Metastatik seminomda Primer RPLND
COTRIMS
ASCO GU 2025
Cáncer de testículo: reinventar la rueda